|Datasheet||Specific Preferences||Reviews||Research Topics||Protocols|
|Vector Type||Mammalian Expression Vector|
|Expression Method||Constiutive ,Stable / Transient|
|Selection In Mammalian Cells||Hygromycin|
A myc tag is a polypeptide protein tag derived from the c-myc gene product that can be added to a protein using recombinant DNA technology. It can be used for affinity chromatography, then used to separate recombinant, overexpressed protein from wild type protein expressed by the host organism. It can also be used in the isolation of protein complexes with multiple subunits.
A myc tag can be used in many different assays that require recognition by an antibody. If there is no antibody against the studied protein, adding a myc-tag allows one to follow the protein with an antibody against the Myc epitope. Examples are cellular localization studies by immunofluorescence or detection by Western blotting.
The peptide sequence of the myc-tag is: N-EQKLISEEDL-C (1202 Da). It can be fused to the C-terminus and the N-terminus of a protein. It is advisable not to fuse the tag directly behind the signal peptide of a secretory protein, since it can interfere with translocation into the secretory pathway.
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, C-GFPSpark-tagged||DG70009-ACG|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, C-FLAG-tagged||DG70009-CF|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, C-His-tagged||DG70009-CH|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, C-Myc-tagged||DG70009-CM|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, C-HA-tagged||DG70009-CY|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone)||DG70009-M|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, N-FLAG-tagged||DG70009-NF|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, N-His-tagged||DG70009-NH|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, N-Myc-tagged||DG70009-NM|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, N-HA-tagged||DG70009-NY|
|Canine IL8 Gene cDNA Clone (full-length ORF Clone), expression ready, untagged||DG70009-UT|
Interleukin 8 (IL-8), also known as CXCL8, which is a chemokine with a defining CXC amino acid motif that was initially characterized for its leukocyte chemotactic activity, is now known to possess tumorigenic and proangiogenic properties as well. This chemokine is secreted by a variety of cell types including monocyte/macrophages, T cells, neutrophils, fibroblasts, endothelial cells, and various tumor cell lines in response to inflammatory stimuli (IL1, TNF, LPS, etc). In human gliomas, IL-8 is expressed and secreted at high levels both in vitro and in vivo, and recent experiments suggest it is critical to glial tumor neovascularity and progression. Levels of IL-8 correlate with histologic grade in glial neoplasms, and the most malignant form, glioblastoma, shows the highest expression in pseudopalisading cells around necrosis, suggesting that hypoxia/anoxia may stimulate expression. Interleukin (IL)-8/CXCL8 is a potent neutrophil chemotactic factor. Accumulating evidence has demonstrated that various types of cells can produce a large amount of IL-8/CXCL8 in response to a wide variety of stimuli, including proinflammatory cytokines, microbes and their products, and environmental changes such as hypoxia, reperfusion, and hyperoxia. Numerous observations have established IL-8/CXCL8 as a key mediator in neutrophil-mediated acute inflammation due to its potent actions on neutrophils. However, several lines of evidence indicate that IL-8/CXCL8 has a wide range of actions on various types of cells, including lymphocytes, monocytes, endothelial cells, and fibroblasts, besides neutrophils. The discovery of these biological functions suggests that IL-8/CXCL8 has crucial roles in various pathological conditions such as chronic inflammation and cancer. IL-8 has been associated with tumor angiogenesis, metastasis, and poor prognosis in breast cancer. IL-8 may present a novel therapeutic target for estrogen driven breast carcinogenesis and tumor progression.